Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 91-100 of 639 results
Neurochemical Research, 2022 • October 26, 2022
The study aimed to investigate the effects of linalyl acetate (LA) on neuropathic pain caused by sciatic nerve injury (SNI) in rats, focusing on the TSLP and IL-33 signaling pathways. The results show...
KEY FINDING: LA attenuated mechanical hyperalgesia in SNI rats, indicating a reduction in pain sensitivity.
Frontiers in Pharmacology, 2022 • October 19, 2022
Muse cells are endogenous pluripotent-like stem cells found in various tissues, exhibiting triploblastic differentiation, self-renewal, stress tolerance, and reparative function. They home to damaged ...
KEY FINDING: Muse cells selectively accumulate at damaged sites by sensing sphingosine-1-phosphate (S1P), a key mediator of inflammation.
Frontiers in Pharmacology, 2022 • October 19, 2022
Neurological diseases pose a significant burden, and their complex pathogenesis necessitates multi-targeted treatments. Traditional Chinese medicine, particularly TWHF extracts like triptolide and cel...
KEY FINDING: Triptolide and celastrol exhibit therapeutic effects in Alzheimer's disease by inhibiting Aβ deposition, reducing neuroinflammation, decreasing ROS levels, attenuating apoptosis, enhancing autophagy, and exerting neurotrophic effects.
GMJ, 2022 • April 24, 2022
This phase II randomized controlled trial investigated the effects of dimethyl fumarate (DMF) on Karnofsky Performance Status (KPS) and serum S100β levels in newly diagnosed glioblastoma (GBM) patient...
KEY FINDING: DMF administration was associated with a statistically significant increase in KPS scores one month after surgery compared to the control group (P=0.001).
PNAS, 2022 • November 7, 2022
This study investigates the role of spinal neuropeptide Y Y1 receptor-expressing neurons (Y1-INs) in neuropathic pain. The researchers found that nerve injury increases the excitability of Y1-INs, lea...
KEY FINDING: Spared nerve injury (SNI) enhances the excitability of Y1-INs and elicits allodynia and affective pain.
Toxins, 2022 • November 10, 2022
Following spinal cord injury (SCI), pathological reflexes develop that result in altered bladder function and sphincter dis-coordination, with accompanying changes in the detrusor. In a rodent model of...
KEY FINDING: BoNT-A injected bladders of SCI rats weighed significantly less than saline injected bladders of SCI rats.
Int. J. Mol. Sci., 2022 • November 18, 2022
The study aimed to investigate the role of H4R in the anti-hyperalgesic action of the H3R antagonist GSK189254 in the spared nerve injury (SNI) model in mice. The results showed that GSK189254 attenua...
KEY FINDING: GSK189254 reversed mechanical and thermal allodynia in SNI mice, but this effect was prevented by blocking H4R with JNJ 10191584.
J. Clin. Med., 2022 • November 11, 2022
This review summarizes recent developments in pharmacotherapy for spinal cord injuries (SCI), focusing on treatments addressing motor dysfunction, spasticity, neuropathic pain, and oxidative stress. T...
KEY FINDING: The review identifies multiple potential therapeutic targets, including modulation of inflammation with nanotherapeutics, heme oxygenases, and apelin-13; reduction of oxidative stress; and neuro-regeneration strategies.
Neural Regeneration Research, 2023 • October 11, 2022
This study investigates the effect of ginsenoside Rb1 (G-Rb1) on energy metabolism in spinal cord injury (SCI) using mouse and cell models. The results demonstrate that G-Rb1 inhibits neuronal oxidati...
KEY FINDING: Ginsenoside Rb1 (G-Rb1) inhibits neuronal oxidative stress, protects mitochondria, promotes neuronal metabolic reprogramming, and increases glycolytic activity and ATP production.
Cell & Bioscience, 2022 • November 3, 2022
The study aimed to develop non-metabolizable pregnenolone (P5) analogs to differentiate the effects of P5 from its metabolites in treating neurodevelopmental diseases. Compound #43 was identified as a...
KEY FINDING: Compound #43 (3-beta-pregnenolone acetate) increases microtubule polymerization in vitro and modifies microtubule dynamics in live cells.